Chen, Z., Brodie, M. J., Ding, D. & Kwan, P. Editorial: epidemiology of epilepsy and seizures. Front. Epidemiol. 3, 1273163 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Devinsky, O. et al. Epilepsy. Nat. Rev. Dis. Prim. 4, 18024 (2018).

Article  PubMed  Google Scholar 

Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia 58, 512–521 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Pitkanen, A., Lukasiuk, K., Dudek, F. E. & Staley, K. J. Epileptogenesis. Cold Spring Harb. Perspect. Med. 5, a022822 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Galanopoulou, A. S. et al. Antiepileptogenesis and disease modification: progress, challenges, and the path forward — Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open 6, 276–296 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Curatolo, P., Moavero, R., van Scheppingen, J. & Aronica, E. mTOR dysregulation and tuberous sclerosis-related epilepsy. Exp. Rev. Neurother. 18, 185–201 (2018).

Article  CAS  Google Scholar 

Vezzani, A., Balosso, S. & Ravizza, T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat. Rev. Neurol. 15, 459–472 (2019). This review describes inflammatory pathways that are activated in pharmaco-resistant epilepsy and can be modulated in animal models to produce therapeutic effects.

Article  CAS  PubMed  Google Scholar 

Aronica, E., Specchio, N., Luinenburg, M. J. & Curatolo, P. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. Brain 146, 2694–2710 (2023). This review provides an overview of the different biological mechanisms throughout the life course, even beyond the epileptogenic process, in individuals with tuberous sclerosis complex.

Article  PubMed  PubMed Central  Google Scholar 

Weichhart, T., Hengstschläger, M. & Linke, M. Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15, 599–614 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein, P. et al. Commonalities in epileptogenic processes from different acute brain insults: do they translate? Epilepsia 59, 37–66 (2018).

Article  CAS  PubMed  Google Scholar 

McDaniel, S. S., Rensing, N. R., Thio, L. L., Yamada, K. A. & Wong, M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia 52, e7–e11 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simeone, T. A., Simeone, K. A. & Rho, J. M. Ketone bodies as anti-seizure agents. Neurochem. Res. 42, 2011–2018 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Girodengo, M., Ultanir, S. K. & Bateman, J. M. Mechanistic target of rapamycin signaling in human nervous system development and disease. Front. Mol. Neurosci. 15, 1005631 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrews, M. G., Subramanian, L. & Kriegstein, A. R. mTOR signaling regulates the morphology and migration of outer radial glia in developing human cortex. eLife 9, e58737 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rostamzadeh, D. et al. mTOR signaling pathway as a master regulator of memory CD8+ T-cells, Th17, and NK cells development and their functional properties. J. Cell Physiol. 234, 12353–12368 (2019).

Article  CAS  PubMed  Google Scholar 

Mühlebner, A., Bongaarts, A., Sarnat, H. B., Scholl, T. & Aronica, E. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives. J. Anat. 235, 521–542 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Gerasimenko, A., Baldassari, S. & Baulac, S. mTOR pathway: insights into an established pathway for brain mosaicism in epilepsy. Neurobiol. Dis. 182, 106144 (2023).

Article  CAS  PubMed  Google Scholar 

Okoh, J. et al. Targeted suppression of mTORC2 reduces seizures across models of epilepsy. Nat. Commun. 14, 7364 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hodges, S. L. & Lugo, J. N. Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy. Epilepsy Res. 161, 106282 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao, Z., Peng, J., Gan, N., Arafat, A. & Yin, F. Interleukin-1β plays a pivotal role via the PI3K/Akt/mTOR signaling pathway in the chronicity of mesial temporal lobe epilepsy. Neuroimmunomodulation 23, 332–344 (2016).

Article  CAS  PubMed  Google Scholar 

Switon, K., Kotulska, K., Janusz-Kaminska, A., Zmorzynska, J. & Jaworski, J. Molecular neurobiology of mTOR. Neuroscience 341, 112–153 (2017).

Article  CAS  PubMed  Google Scholar 

Fernandes, S. A. & Demetriades, C. The multifaceted role of nutrient sensing and mTORC1 signaling in physiology and aging. Front Aging 2, 707372 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Zimmer, T. S. et al. Tuberous sclerosis complex as disease model for investigating mTOR-related gliopathy during epileptogenesis. Front. Neurol. 11, 1028 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Figlia, G., Gerber, D. & Suter, U. Myelination and mTOR. Glia 66, 693–707 (2018).

Article  PubMed  Google Scholar 

Galanopoulou, A. S., Gorter, J. A. & Cepeda, C. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 53, 1119–1130 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curatolo, P., Specchio, N. & Aronica, E. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. Lancet Neurol. 21, 843–856 (2022).

Article  CAS  PubMed  Google Scholar 

Najm, I. et al. The ILAE consensus classification of focal cortical dysplasia: an update proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 63, 1899–1919 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen, L. H. & Bordey, A. Current review in basic science: animal models of focal cortical dysplasia and epilepsy. Epilepsy Curr. 22, 234–240 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Eichmüller, O. L. et al. Amplification of human interneuron progenitors promotes brain tumors and neurological defects. Science 375, eabf5546 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Moavero, R. et al. Genetic pathogenesis of the epileptogenic lesions in tuberous sclerosis complex: therapeutic targeting of the mTOR pathway. Epilepsy Behav. 131, 107713 (2022).

Article  PubMed  Google Scholar 

Bockaert, J. & Marin, P. mTOR in brain physiology and pathologies. Physiol. Rev. 95, 1157–1187 (2015).

Article  CAS  PubMed  Google Scholar 

Talos, D. M. et al. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy. Ann. Neurol. 83, 311–327 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campolo, M. et al. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury. J. Cell Mol. Med. 25, 7855–7866 (2021). This study shows that treatment with mTOR inhibitors ameliorated the neuroinflammation associated with traumatic brain injury showing a diminished neuronal death and astrogliosis after trauma.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Movahedpour, A. et al. Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: a novel insight into targeted therapy. Cell Biochem. Funct. 40, 232–247 (2022).

Article  CAS  PubMed  Google Scholar 

Guo, D., Zeng, L., Brody, D. L. & Wong, M. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS ONE 8, e64078 (2013). This study provides evidence that rapamycin treatment for 1 month after traumatic brain injury decreased the seizure frequency and rate of developing post-traumatic epilepsy, showing inhibition of epileptogenesis.

Article  CAS  PubMed  PubMed Central